"Time Saved" Calculations to Improve Decision-Making in Progressive Disease Studies

Area of Science:

• Neurology
• Clinical Trials
• Biostatistics

Background:

• Disease-modifying therapies (DMTs) show potential in early-stage diseases like Alzheimer's, but interpreting their clinical relevance is challenging due to slow progression.
• Standard clinical trial endpoints may not fully capture the subtle yet significant effects of DMTs.

Purpose of the Study:

• To evaluate the utility of Time Component Tests (TCTs) in quantifying and interpreting the efficacy of DMTs for early Alzheimer's disease.
• To demonstrate how TCTs translate treatment differences into easily understood metrics like 'time saved'.

Main Methods:

• Applied TCT methods to a Phase II clinical trial involving 332 patients with early Alzheimer's disease.
• Utilized composite scales (aADAS, aADL) as co-primary outcomes, alongside standard scales (CDR-sb, ADAS-Cog, ADCS-ADL).
• Compared treatment groups receiving AFFITOPE® AD02 or AD04 with control groups.

Main Results:

• The AD04 2 mg group showed statistically significant effects, but the clinical meaningfulness of a 3.8-point composite difference was unclear.
• TCT analysis revealed a clinically relevant time savings of 11 months over an 18-month study period for the AD04 2 mg group.
• This time savings metric provided a more universally understood measure of treatment effect than the composite score difference.

Conclusions:

• A combined approach using composite outcomes and TCTs enhances the detection and interpretation of DMT effects.
• TCTs offer a powerful, intuitive method for assessing the real-world impact of treatments for progressive neurological diseases.
• The 'time saved' metric derived from TCTs improves the communication of clinical trial results to a broader audience.